APA (7th ed.) Citation

G, D., M, M., A, L., E, G., J, S., Y, V., . . . F, L. (2026). Which trial do we need? Defining the optimal duration of antifungal therapy for invasive pulmonary aspergillosis. Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases, 32(5), 683. https://doi.org/10.1016/j.cmi.2026.01.030

Chicago Style (17th ed.) Citation

G, Desoubeaux, et al. "Which Trial Do We Need? Defining the Optimal Duration of Antifungal Therapy for Invasive Pulmonary Aspergillosis." Clinical Microbiology and Infection : The Official Publication of the European Society of Clinical Microbiology and Infectious Diseases 32, no. 5 (2026): 683. https://doi.org/10.1016/j.cmi.2026.01.030.

MLA (9th ed.) Citation

G, Desoubeaux, et al. "Which Trial Do We Need? Defining the Optimal Duration of Antifungal Therapy for Invasive Pulmonary Aspergillosis." Clinical Microbiology and Infection : The Official Publication of the European Society of Clinical Microbiology and Infectious Diseases, vol. 32, no. 5, 2026, p. 683, https://doi.org/10.1016/j.cmi.2026.01.030.